Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications

Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications

Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression implicated in cancer pathogenesis. Inhibitors of HDACs (HDI) are under investigation as novel anti-cancer drugs, which induce histone hyperacetylation. These agents modulate chromatin structure leadin...

Full description

Bibliographic Details
Main Authors: Aneta Grabarska, Magdalena Dmoszyńska-Graniczka, Ewa Nowosadzka, Andrzej Stepulak
Format: Article
Language:English
Published: Index Copernicus International S.A. 2013-08-01
Series:Postępy Higieny i Medycyny Doświadczalnej
Subjects:
Clinical Trials
angiogenesis
Apoptosis
Cell Cycle
Histone Deacetylase Inhibitors
Online Access:http://journals.indexcopernicus.com/fulltxt.php?ICID=1061381
id doaj-394823b981624a89b9a5fb5a76e1870f
record_format Article
spelling doaj-394823b981624a89b9a5fb5a76e1870f2020-11-24T22:52:27ZengIndex Copernicus International S.A.Postępy Higieny i Medycyny Doświadczalnej0032-54491732-26932013-08-016786368872273510.5604/17322693.1061381 Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applicationsAneta GrabarskaMagdalena Dmoszyńska-GraniczkaEwa NowosadzkaAndrzej StepulakHistone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression implicated in cancer pathogenesis. Inhibitors of HDACs (HDI) are under investigation as novel anti-cancer drugs, which induce histone hyperacetylation. These agents modulate chromatin structure leading to transcriptional changes of a very large number of genes, which affect signaling pathways, inhibit cell cycle progression and angiogenesis, and induce apoptosis in cancer cells. Currently, several HDI are in clinical trials used in monotherapy or in combination with other cytostatics, showing promising anticancer effects. To date, more than 15 HDIs have been found as potential drugs. This paper reviews the molecular mechanisms of HDI action on cancer cells and summarizes clinical trials of the most promising HDIs in the treatment of patients with hematologic malignancies and solid tumors.http://journals.indexcopernicus.com/fulltxt.php?ICID=1061381Clinical TrialsangiogenesisApoptosisCell CycleHistone Deacetylase Inhibitors
collection DOAJ
language English
format Article
sources DOAJ
author Aneta Grabarska
Magdalena Dmoszyńska-Graniczka
Ewa Nowosadzka
Andrzej Stepulak
spellingShingle Aneta Grabarska
Magdalena Dmoszyńska-Graniczka
Ewa Nowosadzka
Andrzej Stepulak
Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications
Postępy Higieny i Medycyny Doświadczalnej
Clinical Trials
angiogenesis
Apoptosis
Cell Cycle
Histone Deacetylase Inhibitors
author_facet Aneta Grabarska
Magdalena Dmoszyńska-Graniczka
Ewa Nowosadzka
Andrzej Stepulak
author_sort Aneta Grabarska
title Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications
title_short Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications
title_full Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications
title_fullStr Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications
title_full_unstemmed Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications
title_sort histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications
publisher Index Copernicus International S.A.
series Postępy Higieny i Medycyny Doświadczalnej
issn 0032-5449
1732-2693
publishDate 2013-08-01
description Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression implicated in cancer pathogenesis. Inhibitors of HDACs (HDI) are under investigation as novel anti-cancer drugs, which induce histone hyperacetylation. These agents modulate chromatin structure leading to transcriptional changes of a very large number of genes, which affect signaling pathways, inhibit cell cycle progression and angiogenesis, and induce apoptosis in cancer cells. Currently, several HDI are in clinical trials used in monotherapy or in combination with other cytostatics, showing promising anticancer effects. To date, more than 15 HDIs have been found as potential drugs. This paper reviews the molecular mechanisms of HDI action on cancer cells and summarizes clinical trials of the most promising HDIs in the treatment of patients with hematologic malignancies and solid tumors.
topic Clinical Trials
angiogenesis
Apoptosis
Cell Cycle
Histone Deacetylase Inhibitors
url http://journals.indexcopernicus.com/fulltxt.php?ICID=1061381
work_keys_str_mv AT anetagrabarska histonedeacetylaseinhibitorsmolecularmechanismsofactionsandclinicalapplications
AT magdalenadmoszynskagraniczka histonedeacetylaseinhibitorsmolecularmechanismsofactionsandclinicalapplications
AT ewanowosadzka histonedeacetylaseinhibitorsmolecularmechanismsofactionsandclinicalapplications
AT andrzejstepulak histonedeacetylaseinhibitorsmolecularmechanismsofactionsandclinicalapplications
_version_ 1725666057896591360

Similar Items